{"transactions":[{"id":4616176,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:17.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":208063,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.5,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":208063},"source":{"system":"sec-edgar","filing":"0001140361-26-036380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036380/form4.xml","form_type":"4"}},{"id":4616175,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:17.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56818,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.28,"expiration_date":"2035-11-04","underlying":"Common Stock","underlying_shares":56818},"source":{"system":"sec-edgar","filing":"0001140361-26-036380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036380/form4.xml","form_type":"4"}},{"id":4616174,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:17.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":103000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.25,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001140361-26-036380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036380/form4.xml","form_type":"4"}},{"id":4616173,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:17.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the \"Company\"), Eli Lilly and Company, an Indiana corporation (\"Parent\"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"), on September 11, 2026, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.34,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001140361-26-036380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036380/form4.xml","form_type":"4"}},{"id":746599,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-06-09T00:00:39.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":86095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date."}],"balance_after":86095,"derivative":{"exercise_price":4.5,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":86095},"source":{"system":"sec-edgar","filing":"0001140361-26-024526","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126024526/form4.xml","form_type":"4"}},{"id":746598,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-06-09T00:00:39.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":121968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date."}],"balance_after":121968,"derivative":{"exercise_price":4.5,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":121968},"source":{"system":"sec-edgar","filing":"0001140361-26-024526","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126024526/form4.xml","form_type":"4"}},{"id":858396,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T13:50:25.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option."}],"balance_after":0,"derivative":{"exercise_price":7.44,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001643875-26-000006","document":"form4-03052026_010321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000164387526000006/form4-03052026_010321.xml","form_type":"4"}},{"id":858395,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T13:50:25.000Z","date":"2026-03-03","kind":"other","planned":false,"acquired":false,"shares":4956,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001643875-26-000006","document":"form4-03052026_010321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000164387526000006/form4-03052026_010321.xml","form_type":"4"}},{"id":890662,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2026-02-20T22:27:05.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.8,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001643875-26-000004","document":"wk-form4_1771626422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000164387526000004/wk-form4_1771626422.xml","form_type":"4"}},{"id":924954,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-02T22:58:25.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":4956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting."}],"balance_after":4956,"source":{"system":"sec-edgar","filing":"0001643875-26-000002","document":"form4-02022026_100221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000164387526000002/form4-02022026_100221.xml","form_type":"4"}},{"id":1005791,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2025-11-07T01:45:17.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":56818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest as to 100% of the underlying shares on the first anniversary of the grant date."}],"balance_after":56818,"derivative":{"exercise_price":5.28,"expiration_date":"2035-11-04","underlying":"Common Shares","underlying_shares":56818},"source":{"system":"sec-edgar","filing":"0001140361-25-040852","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000114036125040852/form4.xml","form_type":"4"}},{"id":1100189,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2025-06-27T21:31:13.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026."}],"balance_after":103000,"derivative":{"exercise_price":2.25,"expiration_date":"2035-06-26","underlying":"Common Shares","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001140361-25-024018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000114036125024018/form4.xml","form_type":"4"}},{"id":1102646,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-06-24T20:25:28.000Z","date":"2025-06-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in three successive equal annual installments over the three-year period measured from the date of grant of June 21, 2025."}],"balance_after":25000,"derivative":{"exercise_price":7.43,"expiration_date":"2035-06-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018080","document":"form4-06242025_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588925018080/form4-06242025_080624.xml","form_type":"4"}},{"id":1252920,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2025-02-22T01:13:27.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":40500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":40500,"derivative":{"exercise_price":1.41,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":40500},"source":{"system":"sec-edgar","filing":"0001643875-25-000003","document":"wk-form4_1740186801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000164387525000003/wk-form4_1740186801.xml","form_type":"4"}},{"id":1273827,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":31.76,"expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273826,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":15.84,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":15917},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273825,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.28,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273824,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.28,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273823,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":290000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":12.6,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273822,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":193050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":193050},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273821,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":5.94,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273820,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":335650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":335650},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273819,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.4,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":167825},"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273818,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":179536,"price":0.55,"value":98744.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents 179,536 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the \"Effective Time\"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273817,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-02-11T14:11:48.000Z","date":"2025-02-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125064,"price":0.55,"value":68785.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (\"Parent\"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the \"Offer Price\") in cash."}],"balance_after":179536,"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1273816,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-02-11T14:11:48.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":5933,"price":1.1,"value":6526.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This purchase of the Issuer's common stock (the \"Common Stock\") on August 14, 2024 resulted in unintentional matching transactions for Section 16(b) reporting purposes. As a result, the Reporting Person has voluntarily paid to the Issuer $52,582.55 prior to the filing of this Form 4, representing the full amount of the profit realized in connection with the matching transactions less expenses, calculated in accordance with Section 16(b). The purchase of Common Stock on August 14, 2024 was matched against the Reporting Person's sale of Common Stock on February 16, 2024 pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":304600,"source":{"system":"sec-edgar","filing":"0001104659-25-011239","document":"tm255946-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465925011239/tm255946-2_4seq1.xml","form_type":"4"}},{"id":1438797,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-08-07T20:05:06.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":12145,"price":1.13,"value":13723.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.15, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":298667,"source":{"system":"sec-edgar","filing":"0001415889-24-020894","document":"form4-08072024_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924020894/form4-08072024_040801.xml","form_type":"4"}},{"id":1473178,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:20:26.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":167825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer."}],"balance_after":167825,"derivative":{"exercise_price":1.4,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":167825},"source":{"system":"sec-edgar","filing":"0001415889-24-017628","document":"form4-06202024_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924017628/form4-06202024_080622.xml","form_type":"4"}},{"id":1473177,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-06-20T20:20:26.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":37300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":310812,"source":{"system":"sec-edgar","filing":"0001415889-24-017628","document":"form4-06202024_080622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924017628/form4-06202024_080622.xml","form_type":"4"}},{"id":1477300,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:06:02.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":0.4,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-24-012720","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000106299324012720/form4.xml","form_type":"4"}},{"id":1478953,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true}}],"security":"Stock Option","published_at":"2024-06-14T21:00:43.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":206000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest as to 1/3rd of the underlying shares on June 13, 2025 and as to the remaining underlying shares in twenty-four (24) substantially equal monthly installments thereafter, such that the option will become fully vested on June 13, 2027."}],"balance_after":206000,"derivative":{"exercise_price":1.34,"expiration_date":"2034-06-13","underlying":"Common Shares","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001140361-24-030208","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000114036124030208/form4.xml","form_type":"4"}},{"id":1559491,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T15:55:23.000Z","date":"2024-03-27","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, representing a right to purchase a total of 250,000 shares of common stock, vested and became exercisable in 48 substantially equal monthly installments beginning on September 6, 2019."}],"balance_after":200000,"derivative":{"exercise_price":4.28,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-009175","document":"form4-03272024_030317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924009175/form4-03272024_030317.xml","form_type":"4"}},{"id":1559490,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-03-27T15:55:23.000Z","date":"2024-03-27","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":4.28,"value":214000.0,"ownership":{"direct":true},"balance_after":273512,"source":{"system":"sec-edgar","filing":"0001415889-24-009175","document":"form4-03272024_030317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924009175/form4-03272024_030317.xml","form_type":"4"}},{"id":1625354,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2024-02-22T21:54:24.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":39500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":39500,"derivative":{"exercise_price":6.81,"expiration_date":"2034-02-19","underlying":"Common Stock","underlying_shares":39500},"source":{"system":"sec-edgar","filing":"0001628280-24-006402","document":"wk-form4_1708638851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000162828024006402/wk-form4_1708638851.xml","form_type":"4"}},{"id":1629203,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-02-21T21:05:24.000Z","date":"2024-02-16","kind":"sale","planned":false,"acquired":false,"shares":11850,"price":9.94,"value":117789.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.88 to $9.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":223512,"source":{"system":"sec-edgar","filing":"0001415889-24-004575","document":"form4-02212024_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924004575/form4-02212024_040201.xml","form_type":"4"}},{"id":1675187,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T21:18:32.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":335650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer."}],"balance_after":335650,"derivative":{"exercise_price":9.74,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":335650},"source":{"system":"sec-edgar","filing":"0001415889-24-001590","document":"form4-01192024_090125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924001590/form4-01192024_090125.xml","form_type":"4"}},{"id":1675186,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-01-19T21:18:32.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":74600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":235362,"source":{"system":"sec-edgar","filing":"0001415889-24-001590","document":"form4-01192024_090125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588924001590/form4-01192024_090125.xml","form_type":"4"}},{"id":1812921,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-08-09T01:05:17.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":30,"price":8.94,"value":268.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":160762,"source":{"system":"sec-edgar","filing":"0001415889-23-011951","document":"form4-08082023_090807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588923011951/form4-08082023_090807.xml","form_type":"4"}},{"id":1812920,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-08-09T01:05:17.000Z","date":"2023-08-07","kind":"sale","planned":true,"acquired":false,"shares":6413,"price":9.55,"value":61244.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the \"Company\") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.18 to $10.15, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":160792,"source":{"system":"sec-edgar","filing":"0001415889-23-011951","document":"form4-08082023_090807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588923011951/form4-08082023_090807.xml","form_type":"4"}},{"id":1849537,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:25:17.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":1.04,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-23-013811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000106299323013811/form4.xml","form_type":"4"}},{"id":1995922,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2023-02-23T22:11:32.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 21, 2024,  subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":21500,"derivative":{"exercise_price":6.12,"expiration_date":"2033-02-20","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001619856-23-000023","document":"wf-form4_167719023966401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000161985623000023/wf-form4_167719023966401.xml","form_type":"4"}},{"id":2042142,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-30T21:45:07.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":360000,"derivative":{"exercise_price":5.94,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0001415889-23-001587","document":"form4-01302023_090159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588923001587/form4-01302023_090159.xml","form_type":"4"}},{"id":2042141,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-01-30T21:45:07.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2024, the second installment vesting on February 15, 2025, and the third installment vesting on February 15, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":167205,"source":{"system":"sec-edgar","filing":"0001415889-23-001587","document":"form4-01302023_090159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000141588923001587/form4-01302023_090159.xml","form_type":"4"}},{"id":2234164,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T21:25:19.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.43,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001062993-22-014805","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000106299322014805/form4.xml","form_type":"4"}},{"id":2255255,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2022-05-26T20:01:50.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":19305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in two equal installments, with the first installment vesting on August 4, 2023, and the second installment vesting on August 4, 2024, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":87205,"source":{"system":"sec-edgar","filing":"0001104659-22-065240","document":"tm2216988-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465922065240/tm2216988-3_4seq1.xml","form_type":"4"}},{"id":2410097,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-07T21:08:27.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":193050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on March 4, 2022."}],"balance_after":193050,"derivative":{"exercise_price":10.4,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":193050},"source":{"system":"sec-edgar","filing":"0001104659-22-012781","document":"tm225605-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465922012781/tm225605-3_4seq1.xml","form_type":"4"}},{"id":2410096,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-07T21:08:27.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":42900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":67900,"source":{"system":"sec-edgar","filing":"0001104659-22-012781","document":"tm225605-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465922012781/tm225605-3_4seq1.xml","form_type":"4"}},{"id":2462444,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2021-12-21T22:20:14.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on December 20, 2022, subject to the reporting person continuing to provide services to the Issuer through each such vesting date."}],"balance_after":27500,"derivative":{"exercise_price":15.16,"expiration_date":"2031-12-19","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-21-070795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919121070795/doc4.xml","form_type":"4"}},{"id":2630562,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2021-07-19T21:33:23.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":13171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":37.52,"underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004980","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000156218021004980/primarydocument.xml","form_type":"4"}},{"id":2630561,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T21:33:23.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":26342,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":10.81,"underlying":"Common Stock","underlying_shares":26342},"source":{"system":"sec-edgar","filing":"0001562180-21-004980","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000156218021004980/primarydocument.xml","form_type":"4"}},{"id":2630560,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T21:33:23.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":13171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":33.57,"underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004980","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000156218021004980/primarydocument.xml","form_type":"4"}},{"id":2680948,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T21:47:00.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":13171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2021, and the shares underlying the option vest in equal quarterly installments through June 2, 2022, subject to continued service."}],"balance_after":13171,"derivative":{"exercise_price":33.57,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004077","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000156218021004077/primarydocument.xml","form_type":"4"}},{"id":2686592,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-02T21:02:06.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":68577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":68577,"derivative":{"exercise_price":1.74,"expiration_date":"2031-05-28","underlying":"Common Stock","underlying_shares":68577},"source":{"system":"sec-edgar","filing":"0001429560-21-000007","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000142956021000007/edgar.xml","form_type":"4"}},{"id":2904353,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-01-20T01:14:23.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":290000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest in 36 equal monthly installments, commencing on 1/31/21."}],"balance_after":290000,"derivative":{"exercise_price":12.6,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":290000},"source":{"system":"sec-edgar","filing":"0001104659-21-005523","document":"tm213599-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465921005523/tm213599-7_4seq1.xml","form_type":"4"}},{"id":3113422,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:33:56.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":9000,"derivative":{"exercise_price":35,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-035846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120035846/doc4.xml","form_type":"4"}},{"id":3113421,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:32:48.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":15641,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in the Merger in exchange for a stock option to acquire 82,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":15641,"derivative":{"exercise_price":9.18,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":15641},"source":{"system":"sec-edgar","filing":"0001209191-20-035845","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120035845/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-13"}},{"id":3113420,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:32:48.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":16214,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in the Merger in exchange for a stock option to acquire 85,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Option Shares shall vest in forty eight (48) approximately equal increments of three hundred thirty seven (337) whole Option Shares beginning on the first day of the first calendar month following December 4, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a \"Vesting Date\"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Stock Options originally noted on Table II of the Reporting Person's Form 4 filed on 1/13/2020, in the amounts of 9,537 shares and 6,676 shares, respectively, with the expiration date of 12/31/2028, have been combined and reported hereto as one Stock Option, pursuant to the Board's approval on 12/04/2018."}],"balance_after":16214,"derivative":{"exercise_price":9.18,"expiration_date":"2028-12-03","underlying":"Common Stock","underlying_shares":16214},"source":{"system":"sec-edgar","filing":"0001209191-20-035845","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120035845/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-13"}},{"id":3113419,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:32:48.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":2861,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred nineteen (119) of the Option Shares shall vest as of the date of the grant, and the remaining Option Shares shall vest in forty six (46) approximately equal increments of fifty nine (59) whole Option Shares beginning on the first day of the first calendar month following the Date of Grant and then on the first day of each of the next forty five (45) months thereafter (each a \"Vesting Date\"), if the Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being May 1, 2022), all of the Option Shares which had not vested by then (being not less than 64 Option Shares) will vest and become exercisable, and that the vesting of all then unvested Option Shares shall be accelerated upon a Change of Control."}],"balance_after":2861,"derivative":{"exercise_price":9.18,"expiration_date":"2028-07-11","underlying":"Common Stock","underlying_shares":2861},"source":{"system":"sec-edgar","filing":"0001209191-20-035845","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120035845/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-13"}},{"id":3118713,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-06-08T22:13:53.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":13171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2020, and the shares underlying the option vest in equal quarterly installments through June 4, 2021, subject to continued service."}],"balance_after":13171,"derivative":{"exercise_price":37.52,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-20-004331","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000156218020004331/primarydocument.xml","form_type":"4"}},{"id":3147288,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-15T21:15:40.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":64103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":64103,"derivative":{"exercise_price":1.05,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":64103},"source":{"system":"sec-edgar","filing":"0001209191-20-029765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120029765/doc4.xml","form_type":"4"}},{"id":3312599,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":15737,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Received in the Merger in exchange for a stock option to acquire 82,500 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":15737,"derivative":{"exercise_price":9.18,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":15737},"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3312598,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":6676,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":6676,"derivative":{"exercise_price":9.18,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":6676},"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3312597,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":9537,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":9537,"derivative":{"exercise_price":9.18,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":9537},"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3312596,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":2861,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option shall vest monthly following August 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":2861,"derivative":{"exercise_price":9.18,"expiration_date":"2028-07-11","underlying":"Common Stock","underlying_shares":2861},"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3312595,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":9537,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly following June 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":9537,"derivative":{"exercise_price":9.18,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":9537},"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3312594,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-14T00:22:29.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares being reported are being issued pursuant to restricted stock unit awards (\"RSUs\"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":26500,"source":{"system":"sec-edgar","filing":"0001209191-20-003243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919120003243/doc4.xml","form_type":"4"}},{"id":3313388,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-01-10T21:54:14.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":1800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest in 36 equal monthly installments, commencing on 1/31/20."}],"balance_after":1800000,"derivative":{"exercise_price":2.07,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":1800000},"source":{"system":"sec-edgar","filing":"0001104659-20-003102","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465920003102/a4.xml","form_type":"4"}},{"id":3323836,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T22:03:39.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":31780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"31,780 shares vest on 12/31/2020."}],"balance_after":31780,"source":{"system":"sec-edgar","filing":"0001209191-20-001165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001165/doc4.xml","form_type":"4"}},{"id":3342339,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-13T21:08:28.000Z","date":"2019-12-13","kind":"purchase","acquired":true,"shares":100000,"price":1.25,"value":125000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001104659-19-072572","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465919072572/a4.xml","form_type":"4"}},{"id":3443538,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock option (right to buy)","published_at":"2019-08-08T20:33:13.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest in 48 equal monthly installments, commencing on 9/6/19."}],"balance_after":1000000,"derivative":{"exercise_price":1.07,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001104659-19-044912","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465919044912/a4.xml","form_type":"4"}},{"id":3506497,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:52:29.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":4967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019."}],"balance_after":5019,"source":{"system":"sec-edgar","filing":"0001179110-19-006919","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000117911019006919/edgar.xml","form_type":"4"}},{"id":3523887,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:29:37.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.34,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-030516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919119030516/doc4.xml","form_type":"4"}},{"id":3626385,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock option (right to buy)","published_at":"2019-02-28T23:58:17.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest in 24 equal monthly installments of 10,000 shares each, commencing on 2/26/19 and continuing until the Reporting Person is terminated under the terms of the Reporting Person's employment agreement with the Issuer, at which time all unvested options to purchase common stock will be forfeited. Vested options will expire on the earlier of the one-year anniversary after Executive's continuous service on the Board of Directors terminates or ten years after the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Options to purchase shares of common stock vest in 24 equal monthly installments of 10,000 shares each, commencing on 2/26/19 and continuing until the Reporting Person is terminated under the terms of the Reporting Person's employment agreement with the Issuer, at which time all unvested options to purchase common stock will be forfeited. Vested options will expire on the earlier of the one-year anniversary after Executive's continuous service on the Board of Directors terminates or ten years after the grant date."}],"balance_after":240000,"derivative":{"exercise_price":3.96,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-19-011636","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000110465919011636/a4.xml","form_type":"4"}},{"id":3646057,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-20T23:45:22.000Z","date":"2019-02-19","kind":"grant","acquired":true,"shares":26342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2019 and is scheduled to vest in equal monthly installments through February 19, 2022, subject to continued service."}],"balance_after":26342,"derivative":{"exercise_price":10.81,"expiration_date":"2029-02-18","underlying":"Common Stock","underlying_shares":26342},"source":{"system":"sec-edgar","filing":"0000899243-19-004314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000089924319004314/doc4.xml","form_type":"4"}},{"id":3714457,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-03T02:14:06.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":126700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"126,700 options vest on 12/31/2019."}],"balance_after":126700,"derivative":{"exercise_price":1.87,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":126700},"source":{"system":"sec-edgar","filing":"0001209191-19-000584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919119000584/doc4.xml","form_type":"4"}},{"id":3804367,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-01T20:21:03.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares vest on December 27, 2018, and one twelfth vest quarterly thereafter, subject to the reporting person's continuous service through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.25,"expiration_date":"2028-09-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-18-052746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919118052746/doc4.xml","form_type":"4"}},{"id":3810893,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-20T20:14:32.000Z","date":"2018-09-18","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,000 shares shall vest on each of 9/18/2019 and 9/18/2020."}],"balance_after":50000,"derivative":{"exercise_price":3,"expiration_date":"2028-09-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-051784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919118051784/doc4.xml","form_type":"4"}},{"id":3917119,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-25T20:18:52.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in full on the earlier of (i) May 23, 2019 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2018."}],"balance_after":10100,"derivative":{"exercise_price":38.32,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001179110-18-007562","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000117911018007562/edgar.xml","form_type":"4"}},{"id":4105612,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-06T00:47:10.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":46.35,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-18-002576","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919118002576/doc4.xml","form_type":"4"}},{"id":4279174,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Strategy & Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-17T00:01:43.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date."}],"balance_after":22000,"derivative":{"exercise_price":44.2,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-17-040677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919117040677/doc4.xml","form_type":"4"}},{"id":4279173,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Strategy & Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-17T00:01:43.000Z","date":"2017-06-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the option shares on May 29, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":44.1,"expiration_date":"2027-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-040677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919117040677/doc4.xml","form_type":"4"}},{"id":4279172,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Strategy & Corp. Dev."}}],"security":"Common Stock","published_at":"2017-06-17T00:01:43.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."}],"balance_after":20982,"source":{"system":"sec-edgar","filing":"0001209191-17-040677","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919117040677/doc4.xml","form_type":"4"}},{"id":4289834,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Strategy & Corp. Dev."}}],"security":"Common Stock","published_at":"2017-06-07T22:57:54.000Z","date":"2017-06-05","kind":"sale","acquired":false,"shares":768,"price":43.321,"value":33270.528,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units."}],"balance_after":9982,"source":{"system":"sec-edgar","filing":"0001209191-17-038416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919117038416/doc4.xml","form_type":"4"}},{"id":4349779,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-19T10:49:09.000Z","date":"2017-04-17","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017."}],"balance_after":14000,"derivative":{"exercise_price":38.96,"expiration_date":"2027-04-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001179110-17-006061","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000117911017006061/edgar.xml","form_type":"4"}},{"id":4527139,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":40595,"kind":"person","name":"Braunstein Scott","position":1,"cik":"0001643875","reported_name":"Braunstein Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Strategy & Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-10T01:22:08.000Z","date":"2016-12-07","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":32.35,"expiration_date":"2026-12-07","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-16-154554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643875/000120919116154554/doc4.xml","form_type":"4"}}]}